Allergan said today it has agreed to sell its global generic pharmaceuticals business to Teva Pharmaceutical Industries for $40.5 billion—a blockbuster deal that ends the buyer’s months-long effort to grow into a global giant by acquiring Mylan.
Under the deal, Teva has agreed to buy Allergan’s legacy Actavis global generics business, including the U.S. and international generic commercial units. Allergan’s generic portfolio includes more than 220 ANDAs pending FDA approval with 74 confirmed First-to-File opportunities.
The transaction is intended to transform Teva into one of the world’s top drugmakers—a goal the company sought to achieve earlier this year by snapping up Mylan. But Mylan rejected Teva’s unsolicited advances, starting with a nearly $40 billion cash-and-stock offer disclosed in April—a month after speculation arose of a possible deal between Teva and Mylan.
“We continue to believe that a combination of Teva and Mylan would have made sense for our companies, our respective stockholders, and the healthcare industry as a whole,” Teva president and CEO Erez Vigodman said in a statement. “Despite our clear commitment to consummating a transaction, and our conviction that we ultimately would have succeeded in acquiring Mylan, we believe we have an even greater opportunity to create compelling, sustainable value for Teva’s stockholders through our transaction with Allergan—and we acted quickly to seize the opportunity.”
Full content: The Wall Street Journal
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google Knew Publishers Would Resist Ad Sales Changes, According to Internal Documents in Antitrust Trial
Sep 13, 2024 by
CPI
Federal Antitrust Trial Explores Potential Impact of Tapestry-Capri Merger
Sep 12, 2024 by
CPI
Australia Targets Big Tech with New Fines for Misinformation
Sep 12, 2024 by
CPI
Mastercard to Acquire Cybersecurity Firm Recorded Future for $2.65 Billion
Sep 12, 2024 by
CPI
Ireland Prime Minister: Apple’s €13 Billion Payment Could Fund Housing and Capital Projects
Sep 12, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Canada & Mexico
Sep 3, 2024 by
CPI
Competitive Convergence: Mexico’s 30-Year Quest for Antitrust Parity with its Northern Neighbor
Sep 3, 2024 by
Francisco Javier Núñez Melgoza
Competition and Digital Markets in North America: A Comparative Study of Antitrust Investigations in Mexico and the United States
Sep 3, 2024 by
Julio Garcia
Recent Antitrust Development in Mexico: COFECE’s Preliminary Report on Amazon and Mercado Libre
Sep 3, 2024 by
Alejandra Palacios Prieto
The Cost of Making COFECE Disappear
Sep 3, 2024 by
Mateo Fernández